SEC Will Not Pursue Shire In Replagal Securities Fraud Case
This article was originally published in The Pink Sheet Daily
Executive Summary
SEC files civil action against former Transkaryotic Therapies CEO Richard Selden, but will not take action against TKT’s new parent company.